1. Home
  2. SLN vs TCI Comparison

SLN vs TCI Comparison

Compare SLN & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$5.75

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Logo Transcontinental Realty Investors Inc.

TCI

Transcontinental Realty Investors Inc.

N/A

Current Price

$36.23

Market Cap

343.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SLN
TCI
Founded
1994
1983
Country
United Kingdom
United States
Employees
116
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
236.2M
343.6M
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
SLN
TCI
Price
$5.75
$36.23
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$39.67
N/A
AVG Volume (30 Days)
168.0K
1.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
N/A
$47,070,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$56.31
Revenue Growth
N/A
N/A
52 Week Low
$1.97
$26.96
52 Week High
$7.78
$59.65

Technical Indicators

Market Signals
Indicator
SLN
TCI
Relative Strength Index (RSI) 59.50 25.34
Support Level $5.07 $26.96
Resistance Level $6.10 $47.17
Average True Range (ATR) 0.49 1.60
MACD 0.16 -1.47
Stochastic Oscillator 65.37 2.76

Price Performance

Historical Comparison
SLN
TCI

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: